Eterna Therapeutics Inc. (Nasdaq: ERNA) is excited to announce that it has entered into an agreement with Lincoln Park Capital Fund, LLC (“LPC”) for up to $10 million in common stock purchases. This is an incredible opportunity for the Company to further realize its goal of providing patients with revolutionary mRNA cell engineering medicines.
Eterna will have full control over the timing and amount of their sales of common stock to LPC, under the recently signed 24-month Purchase Agreement. This Agreement ensures that up to $10 million of Eterna’s shares can be purchased by LPC, and the sales price will be based on the market prices at the time of each sale. However, the commencement of sales is subject to the satisfaction of the conditions in the Agreement, including the successful registration of the resale by LPC with the SEC.
LPC can purchase Eterna’s common stock with no upper limit, and has agreed not to short sell or hedge the stock. There are no warrants, rights of first refusal, or any other costly penalties or liquidated damages provisions included in the Purchase Agreement. Eterna has the freedom to terminate the Agreement at any time and without any cost or penalty.
Eterna is delighted to announce its Agreement with LPC, granting access to a maximum of $10 million in capital. This efficient and flexible financing will enable the company to expand its mRNA-based therapeutic product development capabilities, as well as deploying its extensive portfolio of in-licensed mRNA cell engineering patents through strategic partnerships. Matt Angel, Ph.D., Chief Executive Officer and President of Eterna, believes this financial flexibility will keep the company focused on its long-term goals.
Today, Eterna has filed a Current Report on Form 8-K with the SEC, providing further details about the Agreement and the related registration rights agreement. This report outlines the implications of the Agreement and the related registration rights agreement, granting readers greater insight into the terms of the agreements.
The sale of the securities by Eterna under the Agreement is subject to the Securities Act of 1933, as amended (the “Securities Act”), and cannot be offered or sold in the United States without registration under the Securities Act or an applicable exemption.
We are pleased to announce that there will be an offering of securities available for sale in various states and other jurisdictions! However, these securities cannot be sold until they are properly registered or qualified under the relevant state or other jurisdiction’s securities laws. Don’t miss out on this exciting opportunity to invest in something potentially lucrative!
About Eterna Therapeutics Inc.
Eterna Therapeutics is a pioneering life science company that is harnessing the power of mRNA cell engineering to develop transformative new medicines for patients. Eterna has acquired exclusive access to a portfolio of over 100 patents covering the latest mRNA cell engineering technologies, such as mRNA cell reprogramming, mRNA gene editing, the NoveSlice™ and UltraSlice™ gene-editing proteins, and the ToRNAdo™ mRNA delivery system from Factor Bioscience. With these revolutionary tools, Eterna is on the forefront of revolutionizing the healthcare industry.